Roche Pharmaceutical Development and Sales Overview
NME submissions and their additional indications
Projects in phase II and III
Roche
RG6026
New Molecular Entity (NME)
Additional Indication (Al)
Oncology/Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
RG6058
glofitamab+chemo
1L ctDNA+ high risk
DLBCL
tiragolumab +T
1L PD-L1+ cervical
RG6180
autogene cevumeran
1L melanoma
bepranemab
RG6416
Alzheimer's
zinpentraxin alfa
RG6354
(PRM-151)
RG7314
balovaptan
post-traumatic stress
Other
cancer
myelofibrosis
tiragolumab +T
Lunsumio (mosun) +
disorder
alogabat
RG6058 locally adv esophageal
RG7828
lenalidomide
RG7816
(GABA Aa5 PAM)
✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
PDS-Port Delivery System with ranibizumab
Mosun-mosunetuzumab
*First filed in China
1IONIS managed
cancer
2L FL
ASD
Lunsumio (mosun) +
RG6058
tiragolumab + T
1L non-sq NSCLC
RG7828
Polivy
2L+ DLBCL (US)
RG7845
fenebrutinib
RMS
RG6058
tiragolumab + T
1L PD-L1+mSCCHN
astegolimab
RG6149
(anti-ST2)
RG7845
fenebrutinib
PPMS
COPD
RG6107
RG6058
crovalimab*
PNH (EU, US)
tiragolumab + T
1L PD-L1+ NSCLC
glofitamab + chemo
tiragolumab+T+/-
RG6026
RG6058
chemo
RG62991
2L DLBCL
NSCLC neoadj/adj
ASO factor B
IgA nephropathy
RG7906
ralmitaront
schizophrenia
RG6058
tiragolumab +T
Stage III unresectable
RG7854/
TLR7 ago (3)/ siRNA/
RG6107
crovalimab
sickle cell disease
RG6346/
PDL1 LNA
RG7935
prasinezumab
Parkinson's
1L NSCLC
RG6084
HBV
tiragolumab + T
RG6058
1L esophageal cancer
(CN)
RG6107
crovalimab
aHUS
RG6139
PD1xLAG3
solid tumors
gantenerumab
RG1450
RG6321
preclinical Alzheimer's
Susvimo
inavolisib
RG6026
glofitamab
3L+ DLBCL ✓
RG6321
(PDS)
DME
Susvimo
RG6114
(mPI3K alpha inh)
RG6171
giredestrant
(SERD)
semorinemab
RG6100
RG6179
Alzheimer's
crovalimab*
1L HR+ BC
zinpentraxin alfa
1L ER+/HER2-mBC
giredestrant
brain shuttle
RG6107
RG6321
(PDS)
RG6354
(PRM-151)
RG6171
PNH (CN) ✓
(SERD)
RG6102
gantenerumab
RG62991
gantenerumab
RG1450
prodromal to mild
RG7716
Alzheimer's
DR (US)
Vabysmo
(faricimab)
BRVO/CRVO
IPF
ER+ BC adj
Susvimo
(PDS)
WAMD, 36-week refill
anti-IL-6
DME
ASO factor B
geographic atrophy
Alzheimer's
delandistrogene
giredestrant (SERD) +
latent myostatin +
RG6356
moxeparvovec
RG6171
Phesgo
RG6237
(SRP-9001) DMD (EU)
1L ER+/HER2+ BC
Evrysdi
SMA
CB2 receptor agonist
RG7774
DR
2022
2023
2024
2025 and beyond
Status as of October 18, 2022
55View entire presentation